BioCentury | Apr 5, 2019
Tools & Techniques

Second shot for shRNA

...cell therapies to drive or improve efficacy. In the last two years, bluebird bio Inc., Kanglin Biotech Co. Ltd....
...targeting B cell CLL lymphoma 11A (BCL11A) Sickle cell disease (SCD) Ph I Feb. 2018 Kanglin Biotech Co. Ltd....
...Inc., Dallas, Texas Harvard Medical School, Boston, Mass. Horizon Discovery Group plc (LSE:HZD), Cambridge, U.K. Kanglin Biotech Co. Ltd....
Items per page:
1 - 1 of 1
BioCentury | Apr 5, 2019
Tools & Techniques

Second shot for shRNA

...cell therapies to drive or improve efficacy. In the last two years, bluebird bio Inc., Kanglin Biotech Co. Ltd....
...targeting B cell CLL lymphoma 11A (BCL11A) Sickle cell disease (SCD) Ph I Feb. 2018 Kanglin Biotech Co. Ltd....
...Inc., Dallas, Texas Harvard Medical School, Boston, Mass. Horizon Discovery Group plc (LSE:HZD), Cambridge, U.K. Kanglin Biotech Co. Ltd....
Items per page:
1 - 1 of 1